High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia

Barbara Vannata; Idanna Innocenti; Francesco Autore; Federica Sora'; Patrizia Chiusolo; Giuseppe Leone; Simona Sica; Luca Laurenti

doi:10.1002/ajh.23349

High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia

Barbara Vannata, Idanna Innocenti, Francesco Autore, Federica Sora', Patrizia Chiusolo, Giuseppe Leone, Simona Sica, Luca Laurenti

Risultato della ricerca: Contributo in rivista › Articolo in rivista

2 Citazioni (Scopus)

Abstract

Ofatumumab (Ofa) is a new monoclonal anti-CD20 antibody with a high efficacy in fludarabine- and alemtuzumab-refractory B cell chronic lymphocytic leukemia (B-CLL) [1,2]. Data showing an advantage with the addiction of high dose corticosteroids to the Ofa at standard dose in this type of patients, obtaining an OR rate of 78%, have recently been published in the literature [3].

Lingua originale	English
pagine (da-a)	E133-E133
Rivista	American Journal of Hematology
Volume	87
DOI	https://doi.org/10.1002/ajh.23349
Stato di pubblicazione	Pubblicato - 2012

Keywords

Chronic Lymphocytic Leukemia

Accesso al documento

10.1002/ajh.23349

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{07e964f2681b456291763b06fd3d3537,

title = "High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia",

abstract = "Ofatumumab (Ofa) is a new monoclonal anti-CD20 antibody with a high efficacy in fludarabine- and alemtuzumab-refractory B cell chronic lymphocytic leukemia (B-CLL) [1,2]. Data showing an advantage with the addiction of high dose corticosteroids to the Ofa at standard dose in this type of patients, obtaining an OR rate of 78%, have recently been published in the literature [3].",

keywords = "Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia",

author = "Barbara Vannata and Idanna Innocenti and Francesco Autore and Federica Sora' and Patrizia Chiusolo and Giuseppe Leone and Simona Sica and Luca Laurenti",

year = "2012",

doi = "10.1002/ajh.23349",

language = "English",

volume = "87",

pages = "E133--E133",

journal = "American Journal of Hematology",

issn = "1096-8652",

publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia

AU - Vannata, Barbara

AU - Innocenti, Idanna

AU - Autore, Francesco

AU - Sora', Federica

AU - Chiusolo, Patrizia

AU - Leone, Giuseppe

AU - Sica, Simona

AU - Laurenti, Luca

PY - 2012

Y1 - 2012

N2 - Ofatumumab (Ofa) is a new monoclonal anti-CD20 antibody with a high efficacy in fludarabine- and alemtuzumab-refractory B cell chronic lymphocytic leukemia (B-CLL) [1,2]. Data showing an advantage with the addiction of high dose corticosteroids to the Ofa at standard dose in this type of patients, obtaining an OR rate of 78%, have recently been published in the literature [3].

AB - Ofatumumab (Ofa) is a new monoclonal anti-CD20 antibody with a high efficacy in fludarabine- and alemtuzumab-refractory B cell chronic lymphocytic leukemia (B-CLL) [1,2]. Data showing an advantage with the addiction of high dose corticosteroids to the Ofa at standard dose in this type of patients, obtaining an OR rate of 78%, have recently been published in the literature [3].

KW - Chronic Lymphocytic Leukemia

UR - http://hdl.handle.net/10807/40290

U2 - 10.1002/ajh.23349

DO - 10.1002/ajh.23349

M3 - Article

SN - 1096-8652

VL - 87

SP - E133-E133

JO - American Journal of Hematology

JF - American Journal of Hematology

ER -

High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo